Generic Name and Formulations:
Hydrocortisone acetate 0.5%, polymyxin B (as sulfate) 10000 Units/g, neomycin (as sulfate) 0.35%; crm.
Indications for CORTISPORIN:
Short-term use in corticosteroid-responsive dermatoses with secondary infection.
Apply sparingly and massage in 2–4 times daily.
Do not use in eyes, external ear canal if eardrum perforated. Tuberculous, fungal, or viral lesions.
Intertrigo, diaper or stasis dermatitis or ulceration, extensive burns (neomycin may be absorbed). Avoid prolonged use or on large areas. Use lowest effective dose. Monitor for HPA axis suppression; avoid abrupt cessation if used for chronic conditions. Discontinue if infection persists or worsens or if superinfection occurs. Occlusion: not recommended. Pregnancy (Cat.C). Nursing mothers.
Steroid + antibiotics.
Local irritation, folliculitis, hypertrichosis, dermatitis, sensitization, ototoxicity, nephrotoxicity (if neomycin is significantly absorbed), HPA axis suppression (esp. in children), epidermal and dermal atrophy (esp. in thin-skinned or occluded areas).
Endocrinology Advisor Articles
- Single Blood Sample Highly Predictive for Subsequent Diabetes Diagnosis
- Adjunctive Metformin for Insulin Resistance in T1D: A Clinical Perspective
- Effect of Fructose, Allulose on Postprandial Glucose Regulation in Type 2 Diabetes
- Sex Hormone Levels May Affect Postmenopausal Heart Disease Risk
- Menopausal Hormone Therapy Slows Cognitive Decline in Postmenopausal Women
- Diabetes Treatments
- Metformin May Decrease Colorectal Cancer Risk Among Males With Diabetes
- SGLT2 Inhibitor, GLP-1 Receptor Agonist Combination Treatment for Type 2 Diabetes: Expert Insights
- Semaglutide May Induce Weight Loss in Type 2 Diabetes Despite BMI
- FDA Clears Omnipod DASH System for Diabetes Management
- Effect of Infant Feeding Practices and Gut Microbiota on Overweight in First Year
- Empagliflozin, Linagliptin Combination Therapy vs Linagliptin Monotherapy for Type 2 Diabetes
- Cleared Blood Glucose Monitor Systems Not Always Accurate
- CDC: Obesity Prevalence Higher in Non-Metropolitan Counties
- Vascular Mortality Declining in Adults With Diabetes in the United States